ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox

Novartis

Status: Completed

Conditions: Anemia

Treatments: Drug: Deferasirox

Study type: Observational

Funder types: Industry

Identifiers

NCT00466063

CICL670A2411

Details and patient eligibility

About

This registry will evaluate long-term safety and efficacy of deferasirox in children with transfusional iron overload.

Enrollment: 108 patients

Sex: All

Ages: 2 to 5 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• History of transfusion-dependent anemia.
• History of iron overload

Exclusion criteria

• Patients with non-transfusional hemosiderosis.

Other protocol-defined inclusion/exclusion criteria may apply.

Trial design

108 participants in 1 patient group

ICL670

Description:

ICL670

Treatment:

Drug: Deferasirox